Axsome Therapeutics (AXSM) Work In Process (2022 - 2026)

Axsome Therapeutics has reported Work In Process for 5 years, with the latest figure at $15.5 million in Q1 2026.

• Quarterly Work In Process rose 127.41% year-over-year to $15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.5 million (up 127.41% YoY) and the FY2025 annual result came in at $17.8 million, up 130.95% from the prior year.
• Work In Process slipped to $15.5 million in Q1 2026 per AXSM's latest filing, from $17.8 million in the prior quarter.
• Over five years, Work In Process peaked at $17.8 million in Q4 2025 and troughed at $6.8 million in Q1 2025.
• A 5-year average of $11.0 million and a median of $10.5 million in 2024 frame the typical range for Work In Process.
• The widest YoY moves for Work In Process: up 130.95% in 2025, down 37.64% in 2025.
• Over 5 years, Work In Process stood at $14.0 million in 2022, then slipped by 26.34% to $10.3 million in 2023, then fell by 24.92% to $7.7 million in 2024, then soared by 130.95% to $17.8 million in 2025, then fell by 13.34% to $15.5 million in 2026.
• According to Business Quant data, Work In Process over the past three periods registered $15.5 million, $17.8 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.